Additional file 1: of Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial

Dena Howard(University of Leeds), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Adrian Bloor(The Christie NHS Foundation Trust), David Allsup(University of Leeds), Jamie B. Oughton, Anna Hockaday(University of Leeds), Andy Rawstron, Talha Munir(Leeds Teaching Hospitals NHS Trust), David Phillips, Laura Collett
Figshare
January 1, 2016
10.6084/m9.figshare.4412063
Cited by 0

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k